Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice .2. WAY 100635, SDZ 216-525 and NAN-190

被引:58
作者
Cao, BJ [1 ]
Rodgers, RJ [1 ]
机构
[1] UNIV LEEDS, DEPT PSYCHOL, ETHOPHARMACOL LAB, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND
基金
英国惠康基金;
关键词
anxiety elevated plus-maze; 5-HT1A receptors; alpha(1)-adrenoceptors; WAY; 100635; SDZ; 216-525; NAN-190; prazosin; mice;
D O I
10.1016/S0091-3057(97)00279-7
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
To understand further the role of 5-hydroxytryptamine receptor subtype 1A (5-HT1A) mechanisms in anxiety, the behavioural effects of 5-HT1A receptor antagonists with different selectivity and intrinsic activity were examined using an ethological version of the murine elevated plus-maze test. WAY 100635 (0.03-9.0 mg/kg) produced a behavioural profile indicative of an anxiolyticlike effect, with an apparent bell-shaped dose-response relationship and increases in nonexploratory behaviours at the largest dose tested. SDZ 216-525 exerted a dose-dependent antianxiety action at doses of 0.05-0.8 mg/kg, with some loss of activity at 3.2 mg/kg. In contrast, smaller doses of NAN-190 had a significant effect, whereas higher doses (2.5-10.0 mg/kg) decreased locomotor activity and other active behaviours, a profile similar to that produced by the alpha(1)-adrenoceptor antagonist prazosin (2.5 mg/kg), which also inhibited open arm activity. Findings are discussed in relation to 5-HT1A receptor and alpha(1)-adrenoceptor antagonism and corresponding neurochemical changes. The results of the present series support the view that 5-HT1A receptor antagonists have therapeutic potential in the management of anxiety. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:593 / 603
页数:11
相关论文
共 67 条
  • [51] RODGERS RJ, 1994, ETHOLOGY AND PSYCHOPHARMACOLOGY, P9
  • [52] RODGERS RJ, 1992, BEHAV PHARMACOL, V3, P621
  • [53] FACTOR-ANALYSIS OF SPATIOTEMPORAL AND ETHOLOGICAL MEASURES IN THE MURINE ELEVATED PLUS-MAZE TEST OF ANXIETY
    RODGERS, RJ
    JOHNSON, NJT
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1995, 52 (02) : 297 - 303
  • [54] DIFFERENTIAL-EFFECTS OF WAY-100135 ON THE DECREASE IN 5-HYDROXYTRYPTAMINE RELEASE INDUCED BY BUSPIRONE AND NAN-190
    ROUTLEDGE, C
    GURLING, J
    ASHWORTHPREECE, MA
    DOURISH, CT
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 276 (03) : 281 - 284
  • [55] Routledge C, 1996, BEHAV BRAIN RES, V73, P153
  • [56] DEXMEDETOMIDINE SYNERGISM WITH MIDAZOLAM IN THE ELEVATED PLUS-MAZE TEST IN RATS
    SALONEN, M
    ONAIVI, ES
    MAZE, M
    [J]. PSYCHOPHARMACOLOGY, 1992, 108 (1-2) : 229 - 234
  • [57] SANCHEZ C, 1993, BEHAV PHARMACOL, V4, P269
  • [58] SEROTONERGIC MECHANISMS INVOLVED IN THE EXPLORATORY-BEHAVIOR OF MICE IN A FULLY AUTOMATED 2-COMPARTMENT BLACK-AND-WHITE TEST BOX
    SANCHEZ, C
    [J]. PHARMACOLOGY & TOXICOLOGY, 1995, 77 (01): : 71 - 78
  • [59] SDZ 216-525, A SELECTIVE AND POTENT 5-HT1A RECEPTOR ANTAGONIST
    SCHOEFFTER, P
    FOZARD, JR
    STOLL, A
    SIEGL, H
    SEILER, MP
    HOYER, D
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1993, 244 (03): : 251 - 257
  • [60] THE NOVEL 5-HT(1A)-RECEPTOR ANTAGONIST, SDZ 216-525, DECREASES 5-HT RELEASE IN RAT HIPPOCAMPUS IN-VIVO
    SHARP, T
    MCQUADE, R
    FOZARD, JR
    HOYER, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 (03) : 699 - 702